Concepts (191)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 9 | 2024 | 259 | 1.470 |
Why?
|
| Microbiota | 1 | 2022 | 7 | 0.840 |
Why?
|
| Multiple Myeloma | 2 | 2014 | 11 | 0.840 |
Why?
|
| Colorectal Neoplasms | 4 | 2022 | 656 | 0.800 |
Why?
|
| Adenoma | 1 | 2022 | 100 | 0.760 |
Why?
|
| Early Detection of Cancer | 10 | 2024 | 526 | 0.750 |
Why?
|
| Proteostasis Deficiencies | 1 | 2014 | 1 | 0.480 |
Why?
|
| Amyloidosis | 1 | 2014 | 3 | 0.480 |
Why?
|
| Humans | 33 | 2024 | 18430 | 0.460 |
Why?
|
| Skin Neoplasms | 2 | 2005 | 64 | 0.420 |
Why?
|
| Immunoglobulin D | 1 | 2010 | 1 | 0.370 |
Why?
|
| Multiple Trauma | 1 | 2010 | 2 | 0.370 |
Why?
|
| Rib Fractures | 1 | 2010 | 2 | 0.370 |
Why?
|
| Neoplasms | 3 | 2022 | 457 | 0.360 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 2 | 2022 | 12 | 0.350 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 146 | 0.340 |
Why?
|
| MicroRNAs | 2 | 2021 | 17 | 0.340 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2021 | 57 | 0.330 |
Why?
|
| Electronic Health Records | 4 | 2023 | 747 | 0.330 |
Why?
|
| Heart Failure | 1 | 2014 | 398 | 0.320 |
Why?
|
| Male | 14 | 2022 | 10440 | 0.320 |
Why?
|
| Skin Diseases, Papulosquamous | 1 | 2005 | 1 | 0.250 |
Why?
|
| CD56 Antigen | 1 | 2005 | 1 | 0.250 |
Why?
|
| Killer Cells, Natural | 1 | 2005 | 3 | 0.250 |
Why?
|
| CD4 Antigens | 1 | 2005 | 2 | 0.250 |
Why?
|
| Exanthema | 1 | 2005 | 8 | 0.250 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2005 | 4 | 0.250 |
Why?
|
| Aged | 12 | 2023 | 6417 | 0.250 |
Why?
|
| Female | 16 | 2023 | 13136 | 0.250 |
Why?
|
| Middle Aged | 15 | 2023 | 8284 | 0.240 |
Why?
|
| Occult Blood | 2 | 2022 | 167 | 0.230 |
Why?
|
| ras Proteins | 2 | 2014 | 24 | 0.230 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2014 | 36 | 0.220 |
Why?
|
| Mass Screening | 4 | 2024 | 690 | 0.220 |
Why?
|
| Deductibles and Coinsurance | 1 | 2023 | 31 | 0.220 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 6 | 0.210 |
Why?
|
| United States | 9 | 2023 | 4164 | 0.210 |
Why?
|
| Opportunistic Infections | 1 | 2022 | 8 | 0.210 |
Why?
|
| Prepaid Health Plans | 1 | 2022 | 22 | 0.210 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 51 | 0.210 |
Why?
|
| Delivery of Health Care | 4 | 2019 | 444 | 0.210 |
Why?
|
| Myxoma | 1 | 2002 | 1 | 0.210 |
Why?
|
| Skin Pigmentation | 1 | 2002 | 6 | 0.210 |
Why?
|
| Testicular Neoplasms | 1 | 2002 | 11 | 0.200 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2002 | 15 | 0.200 |
Why?
|
| Biological Specimen Banks | 1 | 2022 | 13 | 0.200 |
Why?
|
| Feces | 1 | 2022 | 88 | 0.200 |
Why?
|
| Population Dynamics | 1 | 2021 | 6 | 0.200 |
Why?
|
| Preventive Medicine | 1 | 2021 | 25 | 0.190 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2021 | 43 | 0.190 |
Why?
|
| Breast Neoplasms | 2 | 2021 | 1037 | 0.190 |
Why?
|
| Transfusion-Related Acute Lung Injury | 1 | 2021 | 1 | 0.190 |
Why?
|
| Transfusion Reaction | 1 | 2021 | 2 | 0.190 |
Why?
|
| Blood Transfusion | 1 | 2021 | 3 | 0.190 |
Why?
|
| Respiratory Insufficiency | 1 | 2021 | 16 | 0.190 |
Why?
|
| Cancer Survivors | 1 | 2022 | 89 | 0.180 |
Why?
|
| Adult | 9 | 2023 | 7910 | 0.180 |
Why?
|
| Colonoscopy | 1 | 2022 | 268 | 0.180 |
Why?
|
| Quality Improvement | 1 | 2022 | 207 | 0.170 |
Why?
|
| Models, Organizational | 1 | 2019 | 65 | 0.170 |
Why?
|
| Prospective Studies | 1 | 2022 | 1314 | 0.160 |
Why?
|
| Genetic Testing | 3 | 2014 | 89 | 0.160 |
Why?
|
| Lung | 3 | 2024 | 62 | 0.150 |
Why?
|
| Aged, 80 and over | 6 | 2023 | 2003 | 0.150 |
Why?
|
| Gene Library | 1 | 2017 | 3 | 0.150 |
Why?
|
| Paraffin Embedding | 1 | 2017 | 6 | 0.150 |
Why?
|
| Cohort Studies | 5 | 2022 | 2672 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 38 | 0.140 |
Why?
|
| Tuberculosis | 1 | 2017 | 20 | 0.140 |
Why?
|
| ErbB Receptors | 2 | 2016 | 7 | 0.140 |
Why?
|
| Serum Albumin | 2 | 2009 | 5 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2024 | 208 | 0.140 |
Why?
|
| Mixed Tumor, Malignant | 1 | 2016 | 1 | 0.140 |
Why?
|
| Mixed Tumor, Mullerian | 1 | 2016 | 1 | 0.140 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 1 | 0.140 |
Why?
|
| Heparin-binding EGF-like Growth Factor | 1 | 2016 | 1 | 0.140 |
Why?
|
| Cell Movement | 1 | 2016 | 5 | 0.140 |
Why?
|
| Uterine Neoplasms | 1 | 2016 | 12 | 0.130 |
Why?
|
| Retrospective Studies | 5 | 2024 | 2550 | 0.130 |
Why?
|
| Angiostrongylus cantonensis | 1 | 2015 | 1 | 0.130 |
Why?
|
| Strongylida Infections | 1 | 2015 | 1 | 0.130 |
Why?
|
| DNA, Helminth | 1 | 2015 | 1 | 0.130 |
Why?
|
| Meningitis | 1 | 2015 | 4 | 0.130 |
Why?
|
| Eosinophilia | 1 | 2015 | 2 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 13 | 0.130 |
Why?
|
| Adolescent | 6 | 2022 | 3798 | 0.130 |
Why?
|
| Smoking | 3 | 2023 | 494 | 0.130 |
Why?
|
| Health Services Research | 1 | 2016 | 264 | 0.130 |
Why?
|
| Glomus Jugulare | 1 | 2013 | 1 | 0.120 |
Why?
|
| Glomus Jugulare Tumor | 1 | 2013 | 1 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 249 | 0.110 |
Why?
|
| Hawaii | 3 | 2022 | 45 | 0.110 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2013 | 16 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 7 | 0.110 |
Why?
|
| Child, Preschool | 3 | 2021 | 1478 | 0.100 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 61 | 0.090 |
Why?
|
| Influenza B virus | 1 | 2010 | 8 | 0.090 |
Why?
|
| Biomarkers | 2 | 2009 | 308 | 0.090 |
Why?
|
| Influenza A virus | 1 | 2010 | 14 | 0.090 |
Why?
|
| Laboratories | 1 | 2010 | 23 | 0.090 |
Why?
|
| Disease Outbreaks | 1 | 2010 | 39 | 0.090 |
Why?
|
| Fatty Acids | 1 | 2009 | 8 | 0.080 |
Why?
|
| Acute Coronary Syndrome | 1 | 2009 | 17 | 0.080 |
Why?
|
| Myocardial Infarction | 2 | 2009 | 249 | 0.080 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2020 | 19 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 188 | 0.080 |
Why?
|
| Mutation | 3 | 2014 | 132 | 0.080 |
Why?
|
| Health Status Disparities | 2 | 2020 | 153 | 0.080 |
Why?
|
| Child | 3 | 2021 | 2571 | 0.080 |
Why?
|
| Incidence | 2 | 2022 | 1314 | 0.080 |
Why?
|
| Myocardial Ischemia | 2 | 2009 | 24 | 0.080 |
Why?
|
| Young Adult | 3 | 2022 | 2518 | 0.070 |
Why?
|
| Influenza, Human | 1 | 2010 | 282 | 0.070 |
Why?
|
| Data Collection | 2 | 2019 | 275 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2021 | 237 | 0.060 |
Why?
|
| Insulinoma | 1 | 2005 | 1 | 0.060 |
Why?
|
| Infant | 2 | 2021 | 1245 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 333 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 337 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2016 | 1296 | 0.060 |
Why?
|
| Neoplasm Metastasis | 2 | 2014 | 33 | 0.060 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2014 | 25 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2023 | 7 | 0.060 |
Why?
|
| Cobalt | 1 | 2003 | 1 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 1 | 2005 | 69 | 0.060 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2022 | 7 | 0.050 |
Why?
|
| Cushing Syndrome | 1 | 2002 | 1 | 0.050 |
Why?
|
| Neurilemmoma | 1 | 2002 | 1 | 0.050 |
Why?
|
| Medicare | 1 | 2023 | 214 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2019 | 1143 | 0.050 |
Why?
|
| Prognosis | 2 | 2014 | 624 | 0.050 |
Why?
|
| Community-Based Participatory Research | 1 | 2021 | 63 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 36 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 38 | 0.050 |
Why?
|
| Prevalence | 1 | 2023 | 911 | 0.050 |
Why?
|
| International Classification of Diseases | 1 | 2021 | 87 | 0.050 |
Why?
|
| Hospitals | 1 | 2021 | 80 | 0.040 |
Why?
|
| Inpatients | 1 | 2021 | 80 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2022 | 217 | 0.040 |
Why?
|
| Community Health Planning | 1 | 2019 | 20 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 292 | 0.040 |
Why?
|
| Geography | 1 | 2019 | 41 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 365 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 4 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 8 | 0.040 |
Why?
|
| Tobacco Use Cessation | 1 | 2019 | 23 | 0.040 |
Why?
|
| Registries | 1 | 2022 | 490 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 41 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 45 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 327 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2019 | 29 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2019 | 100 | 0.040 |
Why?
|
| Research | 1 | 2019 | 73 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2023 | 974 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 143 | 0.040 |
Why?
|
| Counseling | 1 | 2019 | 197 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2017 | 4 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 673 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2017 | 43 | 0.040 |
Why?
|
| Protein Binding | 2 | 2009 | 9 | 0.040 |
Why?
|
| Integrin alpha5 | 1 | 2016 | 1 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 1 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 46 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 83 | 0.030 |
Why?
|
| Hospitalization | 1 | 2021 | 847 | 0.030 |
Why?
|
| Animals | 1 | 2015 | 261 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 150 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2013 | 37 | 0.030 |
Why?
|
| Family Health | 1 | 2013 | 49 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 105 | 0.030 |
Why?
|
| Medical Records | 1 | 2013 | 106 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 100 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2012 | 167 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 131 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 65 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2012 | 253 | 0.030 |
Why?
|
| Survival Rate | 1 | 2012 | 269 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 598 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2010 | 17 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 27 | 0.020 |
Why?
|
| Sentinel Surveillance | 1 | 2010 | 14 | 0.020 |
Why?
|
| Quality Control | 1 | 2010 | 48 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2012 | 256 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 962 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 321 | 0.020 |
Why?
|
| Risk Factors | 1 | 2014 | 3449 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2005 | 20 | 0.020 |
Why?
|
| Pancreas | 1 | 2005 | 14 | 0.020 |
Why?
|
| Binding Sites | 1 | 2003 | 2 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 2003 | 5 | 0.010 |
Why?
|
| ROC Curve | 1 | 2003 | 83 | 0.010 |
Why?
|
Concepts
(191)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(11)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->